Vital Signs - Lower is Better - A Blockbuster in Limbo


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on May 12, 2008, provides an strategic overview of current market issues facing Merck Schering-Plough's cholesterol drug, Vytorin. Additionally, a company spotlight is provided for Vical, a biopharmaceutical company developing medicines based on the company's proprietary DNA delivery technologies. Reimbursement and regulatory news from the FDA is also provided for the week of April 28 - May 2, 2008.

Table of Contents

Vital Signs - Lower is Better - A Blockbuster in LimboVital Signs: 12 May 2008This week's issue:

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.